PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel.
* PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC);
* PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC);
* PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).

开始日期2025-01-29

申办/合作机构

EMD Serono Research & Development Institute, Inc.

[+2]

NCT06806046

/ Recruiting临床1期

A Phase 1, Open-label Study of AntiCEACAM5 AntibodyDrug Conjugate M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)

The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).

开始日期2024-12-20

申办/合作机构

Merck Healthcare KGaA

[+1]

NCT05464030

/ Recruiting临床1期

A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2).
Study details include:
* Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2
* M9140 is not available through an expanded access program

开始日期2022-08-04

申办/合作机构

EMD Serono Research & Development Institute, Inc.

[+1]

100 项与 Precemtabart tocentecan 相关的临床结果

登录后查看更多信息

100 项与 Precemtabart tocentecan 相关的转化医学

登录后查看更多信息

100 项与 Precemtabart tocentecan 相关的专利（医药）

登录后查看更多信息

项与 Precemtabart tocentecan 相关的文献（医药）

2025-04-01·INTERNATIONAL JOURNAL OF TOXICOLOGY

The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD

Article

作者: Mueller, Gundi ; Vigna, Enrico ; Bertotti, Elisa ; Salve, Ilse De ; Onidi, Manuela ; Sloot, Willem N. ; Tavano, Patrizia ; Paoletti, Andrea

The therapeutic window of antibody drug-conjugates (ADC) remains challenging due to safety issues such as interstitial lung disease (ILD) observed with specific deruxtecan-based ADCs. To avoid ILD, we designed M9140 by conjugating the maleimide-containing hydrophilic β-glucuronide linker to exatecan and our anti-CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5) specific antibody. Following repeated iv-infusion at 3 to 30 mg/kg of M9140 every 3 weeks, the pathological findings obtained in cynomolgus monkeys were confined to gastrointestinal and hematolymphoid tissues and resembled the toxicity of exatecan. At 24 mg/kg or higher, transient reductions in neutrophil and reticulocyte counts were observed with each dosing event along with reversible anemia throughout the study. The no observed adverse effect level was 24 mg/kg and the maximum tolerated dose was 30 mg/kg. The difference in toxicity by this small dose increment was correlated with a 2.5-fold difference in plasma exatecan exposure indicating antigen-independent toxicity. As anticipated, no lung toxicity was found with M9140 in these studies that were similar in study design to those used to confirm ILD with trastuzumab-deruxtecan in monkeys. Since the non-human primate model is regarded as predictive for the ILD risk in humans, this result indicates a low risk for ILD when applying M9140 to patients. The current M9140 safety data are discussed with special focus on the absence or presence of ILD with other antibody camptothecin-conjugates, for which a hypothetical pathogenic mechanism is postulated here. The favorable nonclinical profile of M9140 warrants further investigation in patients with CEACAM5-overexpressing tumors.

NATURE MEDICINE

Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Article

作者: Kopetz, Scott ; Boni, Valentina ; Siddiqui, Abdul ; Rodriguez-Rivera, Ildefonso ; Habermehl, Christina ; Vieito, Maria ; Courlet, Perrine ; Raab-Westphal, Sabine ; Hart, Felix ; Pallis, Athanasios ; Raghav, Kanwal P S ; Kato, Ken ; Sloot, Willem

Abstract:

CEACAM5, a cell surface protein, is overexpressed in colorectal cancer (CRC). Precemtabart tocentecan (Precem-TcT, previously M9140) is an anti-CEACAM5 antibody–drug conjugate with the topoisomerase 1 inhibitor exatecan as payload. Precem-TcT demonstrated strong antitumor activity and potent bystander activity in preclinical models. Its toxicity profile in cynomolgus monkeys was consistent with that of exatecan. In the dose-escalation stage of the phase 1 trial of Precem-TcT (PROCEADE-CRC-01), 40 heavily pretreated patients with irinotecan-refractory metastatic CRC received Precem-TcT every 3 weeks across seven dose levels (DLs, 0.6–3.2 mg kg−1). Primary endpoints were dose-limiting toxicities (DLTs), adverse events and preliminary clinical activity to establish the recommended dose(s) for expansion (RDEs). Secondary endpoints included pharmacokinetic parameters, objective response and median progression-free survival (mPFS). At the planned, end-of-dose-escalation analysis with extended follow-up (cutoff: 1 August 2024), seven patients had experienced DLTs, primarily hematologic events at 3.0 mg kg−1 and 3.2 mg kg−1. A treatment-related death, also deemed disease related, was reported in a patient with multiple comorbidities and grade 3 obesity. The maximum tolerated dose was determined to be 2.8 mg kg−1 every 3 weeks. Total and conjugated antibody pharmacokinetic profiles largely overlapped, indicating stability of the linker–payload (β-glucuronide–exatecan) in circulation. After a median treatment of 19.1 weeks (range: 1.7–48.3), three of 40 patients (7.5%) had confirmed partial responses (15.0% (6/40) unconfirmed), all at DLs ≥2.4 mg kg−1. mPFS was 5.9 months (95% confidence interval: 4.6–7.2); at DLs ≥2.4 mg kg−1 (n = 34), mPFS was 6.7 months (95% confidence interval: 4.6–8.8). Four patients (10.0%) remained on treatment at cutoff. These early clinical data corroborate preclinical findings, showing predictable safety and encouraging antitumor activity of Precem-TcT at DLs ≥2.4 mg kg−1, with no interstitial lung disease or ocular toxicity. The dose-optimization part at the RDEs of 2.4 mg kg−1 and 2.8 mg kg−1 (both every 3 weeks) in PROCEADE-CRC-01 is ongoing. ClinicalTrials.gov identifier: NCT05464030.

项与 Precemtabart tocentecan 相关的新闻（医药）

2025-09-08

·Bioconjugate 药研备忘

专利动态（2025.09.04）|ADAM9、CEACAM5、CDH3、MUC17等多个靶点ADC项目专利公开

MacroGenics WO2025184362 ADAM9 ADC MGC028 9月4日，MacroGenics 公开一篇 ADC 专利，涉及靶点 ADAM9，抗体为 MGA027，采用 Synaffix 的药物连接子和糖基偶联平台技术，载荷为 Exatecan，DAR 值约为4。 ADAM9（解整合素和金属蛋白酶结构域 9）是多功能 1 型跨膜蛋白 ADAM 家族的成员，在肿瘤发生和癌症进展中发挥作用，并在多种癌症中过度表达，使其成为癌症治疗的有吸引力的靶点。 MGC028 是 MacroGenics 开发的第二款 ADAM9 靶向 ADC，基于 Synaffix 的糖基偶联 GlycoConnect™、亲水性连接子 HydraSpace™ 和TOP1抑制剂 SYNtecan E™ 平台技术。MacroGenics 相信 Synaffix 的方法相对于其他拓扑异构酶I抑制剂基 ADCs 可能具有以下优势：Exatecan 比 SN38 和 deruxtecan 等其他 TOP1 抑制剂具有更强的活性，并且对多药耐药（MDR）机制更不敏感。此外，将 SYNtecan 特异性地连接到 Fc 结构域中通常糖基化的氨基酸，消除了 Fcγ 受体和甘露糖受体的结合，这些结合导致 ADCs 在肺泡巨噬细胞中的非靶向摄取，并且据报道与肺毒性相关，因此消除这种结合可能为患者提供安全益处。 MGC028 目前正在进行一项 1 期首次人体临床研究，旨在评估 MGC028 在晚期实体瘤中的安全性、耐受性、剂量限制性毒性（DLT）和最大耐受剂量（MTD）或最大给药剂量（如果未定义 MTD）。 BMS WO2025184211 CEACAM5-TOPO1 ADC 9月4日，BMS公开一篇ADC专利，靶点涉及CEACAM5，筛选的优选抗体为 MBN001，该抗体经半胱氨酸巯基与乙炔基磷酸接头偶联偶联，搭载可裂解的二肽连接子 VC 与具有旁观者效应的有效载荷 exatecan，得到 ADC 药物 ADCV001，DAR 值为 8。体内抗肿瘤研究表明，在 MKN45 小鼠模型中，对比 M9140，ADCV001 在 3 mg/kg 和 10 mg/kg 剂量下能更有效抑制肿瘤生长和减小肿瘤大小。 CEACAM5 是一种细胞表面蛋白，在正常上皮组织（包括结肠、食道、头颈部、胃和宫颈组织）中表达较弱，但在多种肿瘤类型（包括结直肠癌、胃肠道癌、肺癌和乳腺癌）中高表达，其中在超过80%的结直肠癌中表达最高。在正常组织中，CEACAM5保护管腔器官免受微生物侵袭。在肿瘤细胞中，CEACAM5 与细胞分化、细胞粘附、肿瘤侵袭和转移功能相关。 BMS 官网显示其 CEACAM5-TOPO1 ADC 新药目前已在 1 期临床研究中，针对实体瘤。 2023年4月24日，百时美施贵宝（BMS）和Tubulis公司宣布达成一项达10亿美元的战略许可协议，BMS 获得使用 Tubulis 的 Tubutecan 有效载荷的独家权利，结合 Tubulis 专有的 P5 偶联平台（定点偶联新技术 | 炔基氧化膦用于模块化生物偶联），用于开发选定数量的高度差异化 ADC 来治疗实体瘤。本专利公开的 linker-payload 技术即来源于本次交易中 Tubulis 的授权。 PERSEUS WO2025183174 CDH3 ADC PPMX-T004 9月4日，Perseus Proteomics Inc. 和 UBE 株式会社公开一篇 ADC 专利，Perseus 单独公开一篇抗体专利（WO2025183075），均涉及靶点 CDH3。专利公开优选的抗体为 T004b，通过半胱氨酸的巯基偶联单链单载荷的 PGAP-1 或者单链双载荷 PGAP-2，获得 ADC3（DAR~8）、ADC4（DAR~14）、ADC5（DAR~4）、ADC6（DAR~4）和 ADC7（DAR~4），连接子-有效载荷均为含内酯的 Asn-Val-Cit-PABC-磷酸酯-Auristatin E。体内抗肿瘤研究结果显示，在人胰腺癌 BxPC3 小鼠模型中，相同单剂量 0.5 mg/kg 的不同DAR值ADC药物 ADC3、ADC5 或 ADC7，表现出相当的显著抗肿瘤疗效。 CDH3（P-钙粘蛋白）是一种细胞膜表面抗原，它在细胞粘附过程中发挥作用。Perseus 官网管线公开了一种 CDH3 靶向 ADC 药物 PPMX-T004，目前处于早期研发阶段。 UBE 株式会社在 2023 年公开两篇单链双载（Y 型）的ADC专利（WO2023234426 / WO2023234427），涉及含内酯基和磷酰基修饰的连接子，提高 ADC 药物在血液中的稳定性和抗肿瘤效果。2024年10月21日 UBE 官网消息，Perseus 和 UBE 达成研究协议，将合作开发 ADC 药物，重点关注有前景的候选药物 PPMX-T004 及其他探索性 ADC 研究。根据专利公开情况，PPMX-T004 项目由 Perseus 提供抗体，UBE 提供连接子-有效载荷平台，优选DAR4。第一三共 WO2025183065 / WO2025183064 ISAC：EGFR-STING、CDH6-STING 9月4日，第一三共公开两篇 ISAC 专利，涉及靶点分别为 EGFR、CDH6。采用 SITNG 激动剂环二核苷类作为有效载荷，利用糖基定点偶联实现 DAR2或4 ISAC 的制备，优选 DAR4。体内研究表明，在小鼠移植瘤模型中，ISAC 与其他抗肿瘤药物（吉西他滨、甲磺酸奥西替尼等）或免疫检查点抑制剂（抗PD-1抗体或抗CTLA4抗体）联合给药时显示出显著的抗肿瘤效果。中美华东 WO2025180469 MUC17 ADC HDM2012 9月4日，中美华东制药公开一篇 ADC 专利，涉及靶点 MUC17。专利公开的优选 ADC 结构为 M21-17-Cpd3，抗体 M21-17 通过半胱氨酸巯基与甲磺酸嘧啶接头偶联，搭载亲水性酶可裂解连接子 PEG8-VA-PABC 和有效载荷 Exatecan，DAR 7.87。中美华东制药在今年6月公开其自主研发的一款靶向人粘蛋白-17（Mucin 17，MUC-17）的新型 ADC 药物 HDM2012 已完成中美双报的 IND 申请（全球唯一！华东医药MUC17 ADC HDM2012临床研究加速），适应症为晚期实体瘤。据介绍，HDM2012 是由抗 MUC-17 的单克隆抗体与拓扑异构酶I抑制剂通过可裂解连接子偶联而成，药物抗体偶联比（DAR）为 8。临床前研究结果显示，HDM2012 具有良好的成药性、安全性和有效性，在多个肿瘤模型中表现出优异的抗肿瘤效果；在动物试验中耐受性良好。往期分享：专利动态|XDC专利更新：多种新型有效载荷（2025.08.28）专利动态|XDC的新linekr或新靶点专利动态|偶联药物新专利（2025.08.14）专利动态|新一周的ADC专利（2025.08.07）专利动态|最新偶联药物（XDC）专利（2025.07.31）专利动态 | 新ADC专利公开：新机制载荷/新靶点/新项目(2025.07.24) 专利分享|糖基偶联新型二糖连接子：齐鲁 vs GlycoT 专利动态 | 最新ADC药物相关专利专利动态 | 在研ADC最新专利公开专利分享 | 先声药业FGFR2b ADC药物SIM0686 专利分享 | 亲合力生物的白蛋白偶联药物 QHL-1618，肿瘤微环境释放专利分享 | 新型ADC载荷靶向破解肿瘤耐药专利分享 | "孤勇者"的妥协？Heidelberg Pharma获华东医药投资后转向TOP1i ADC 专利分享 | 先声药业ADC偶联"接头"新技术公开专利分享 | MTG酶定点偶联+点击化学：Hummingbird 双载荷ADC技术公开上海诗健生物新一代ADC平台专利公开 **说明：本公众号内容基于公开信息的整理和分析，如涉及侵权请联系处理；作者水平有限，对专利或文献的解读可能存在疏漏之处，请以原文为准；欢迎个人转发分享，如需转载至公众号或其他平台，请注明出处并遵守版权规范。** 参考资料：公司官网 clinicaltrials.gov 官网 Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - Tubulis Perseus Proteomics 和 UBE 的 ADC 新合作 | Nasdaq --- Perseus Proteomics and UBE’s New ADC Collaboration | Nasdaq END 欢迎关注，与您分享偶联药物领域最新突破

抗体药物偶联物临床1期引进/卖出

2025-08-11

·癌度

《癌度早报》2025年8月11日

临床试验病友交流群（点击）一、新药快讯 1、美国FDA加速批准HER2口服靶向药宗格替尼上市本年度8月8日，美国药品监督管理局FDA加速批准宗格替尼上市，用于治疗HER2结构域激活突变且经过系统性治疗的晚期非鳞状非小细胞肺癌，宗格替尼是一款具有高度选择性的HER2抑制剂，对于所有主要的HER2突变都有强效的抑制活性，曾经获得FDA授予突破性疗法和快速通道资格。基于一项临床试验，71名患者使用该药的治疗应答率达到了75%，58%的患者持续缓解时间大于6个月。对于使用过抗体偶联药的患者宗格替尼的治疗应答率为44%，27%的患者缓解持续时间大于6个月。 2、靶向MET的抗体偶联药MHB042C首次获批临床近日，CDE官网显示，注射用的MHB042C获批临床，用于治疗晚期实体瘤患者。该药是一款MET靶点的抗体偶联药，在2025年AACR大会公布了该药的临床前结果，对于c-MET阳性癌细胞系具有强大的细胞毒性，在动物模型中对肺癌的移植肿瘤病灶有显著的抑制活性，而且总体安全性良好，无脱靶的毒性。 3、CEACAM5抗体偶联药公布临床结果，四线治疗肠癌疾病控制率60% 最近，美国德州MD安德森癌症中心的研究团队发布研究成果，靶向CEACAM5的抗体偶联药Precem-TcT首次人体临床试验结果公布，在每公斤体重2.4毫克以上剂量组，该药治疗的客观缓解率为8.8%，疾病控制率达到了58.8%，近60%。该药靶点CEACAM5在肠癌高度表达，本次临床试验入组了40名肠癌患者，都是前期经过大量治疗疾病进展且难治的患者，80%以上患者接受了三线或以上治疗，因此这款药的疗效数据可以说相当不错！ 4、瑞康曲妥珠单抗联合阿得贝利拟纳入三阴乳腺癌突破性疗法近日，CDE官网显示，瑞康曲妥珠单抗（代号SHR-A1811）联合PD-L1抑制剂阿得贝利单抗拟纳入突破性治疗，适应症为PD-L1阳性表达的局部复发不可切除的三阴性乳腺癌的一线治疗，瑞康曲妥珠单抗是一款靶向HER2的抗体偶联药，今年5月份该药在中国获批上市，单药用于治疗存在HER2激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌。治疗三阴性乳腺癌的适应症源自一项临床研究，上述两款药联合的治疗应答率达到了66.7%，PD-L1阳性患者的应答率达到77.8%。

突破性疗法AACR会议快速通道临床结果上市批准

2025-06-02

·Pharmaceutical Technology

ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

MSD investigated the KRAS G12C inhibitor in patients with solid tumours, including advanced colorectal cancer and non-small cell lung cancer. Image credit: Shutterstock / Atmosphere1. MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination with other oncology drugs. Announcing the data at the American Society of Clinical Oncology (ASCO) meeting 2025, being held from 30 May to 3 June in Chicago, MSD said that MK-1084 was also safe and tolerable in patients with solid tumours, including advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), in the Phase I KANDLELIT-001 trial (NCT05067283). In patients with CRC, there was a 38% confirmed overall response rate (ORR) in the monotherapy arm. When used in combination with Erbitux (cetuximab), there was a 46% confirmed ORR, and when used with both Erbitux and mFOLFOX6(oxaliplatin and leucovorin plus 5-fluorouracil), the confirmed ORR was 38%. Investigators also reported 43% unconfirmed ORR with MK-1084 alone, 56% in combination with Erbitux and 66% in combination with Erbitux and mFOLFOX6. In patients with NSCLC, there was an ORR of 38% in the monotherapy arm, 77% when it was used in combination with Keytruda (pembrolizumab), and 53% when used with Keytruda and chemotherapy (carboplatin and pemetrexed). In all arms, MSD states that MK-1084 had a manageable safety profile. Treatment-related adverse events (AEs) occurred in 58% of patients in the MK-1084 monotherapy arm; 94% of patients in the MK-1084 and Keytruda arm;, 93% of patients in the MK-1084, Keytruda and chemotherapy arm; 95% of patients in the MK-1084 and Erbitux arm; and 97% of patients in the MK-1084 with Erbitux and mFOLFOX6 arm. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence MSD Research Laboratories SVP and oncology, global clinical development Dr Marjorie Green said: “We are encouraged by the promising early data from the KANDLELIT-001 study and look forward to further researching the potential for MK-1084, as monotherapy or in combinations, including with Keytruda in certain settings in patients with KRAS mutations, which are among the most prevalent mutations in cancer.” MSD is also investigating the KRAS G12C in several Phase III trials, including the Phase III KANDLELIT-012 study in patients with unresectable or metastatic CRC with KRAS G12C-mutated tumours and the Phase III KANDLELIT-004 study in patients with NSCLC with KRAS G12C-mutated tumours that express PD-L1 (NCT06345729). ASCO updates MSD also reported data from a Phase II/III study of zilovertamab vedotin as a combination therapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study achieved a 56.3% ORR. Other major pharmaceutical companies have also revealed data around the ASCO 2025 conference. Pfizer announced data from its Phase III BREAKWATER study of Braftovi (encorafenib) in combination with Erbitux and mFOLFOX6. Merck KGaA also highlighted success in two studies, a Phase III trial of its CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumour (TGCT) patients and a Phase I study of M9140, a CEACAM5-targeting antibody-drug conjugate (ADC), in patients with metastatic CRC . Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

临床1期ASCO会议临床结果临床3期抗体药物偶联物

100 项与 Precemtabart tocentecan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床2期	美国	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	中国	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	日本	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	澳大利亚	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	奥地利	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	法国	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	德国	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	意大利	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	韩国	Merck Healthcare KGaA	2025-04-03
转移性非小细胞肺癌	临床2期	西班牙	Merck Healthcare KGaA	2025-04-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05464030 (PROCEADE-CRC-01, Pubmed) 人工标引	临床1期	转移性结直肠癌	40	Precemtabart tocentecan (Dose escalation (0.6-3.2 mg kg−1))	鹹構壓網衊鹹憲願壓繭(範淵淵範餘遞積衊願夢) = 繭糧鑰艱構醖襯網選餘構顧蓋繭製淵鹽構繭遞 (餘壓夢憲構簾鹹蓋鑰構 ) 更多	积极	2025-07-30
NCT05464030 (PROCEADE CRC-01, ASCO2025) 人工标引	临床1期	转移性结直肠癌	60	Precemtabart tocentecanPrecemtabart tocentecan 2.8 mg/kg Q3W	鏇壓衊淵願齋範衊齋憲(選襯艱選廠衊醖網膚遞) = 醖範鬱遞窪糧艱淵積製顧繭糧膚範簾簾網鏇構 (廠鏇鏇積襯憲選選糧蓋 ) 更多	积极	2025-05-30
NCT05464030 (PROCEADE CRC-01, ASCO2025) 人工标引	临床1期	转移性结直肠癌	60	Precemtabart tocentecanPrecemtabart tocentecan 2.4 mg/kg Q3W	鏇壓衊淵願齋範衊齋憲(選襯艱選廠衊醖網膚遞) = 膚鹽膚襯糧築獵壓築獵顧繭糧膚範簾簾網鏇構 (廠鏇鏇積襯憲選選糧蓋 ) 更多	积极	2025-05-30
NCT05464030 (ESMO2024) 人工标引	临床1期	转移性结直肠癌三线 KRAS \| NRAS \| BRAF mutation status	40	M9140 ≥2.4 mg/kg	鬱廠繭鹹醖齋艱蓋淵鹹(構構夢鑰憲淵糧衊淵顧) = 糧構襯顧憲廠鑰醖窪顧繭鏇築選艱構廠鬱糧網 (鹽夢繭壓憲遞壓衊鹹觸 ) 更多	积极	2024-09-16
NCT05464030 (ESMO2024) 人工标引	临床1期	转移性结直肠癌三线 KRAS \| NRAS \| BRAF mutation status	40	M9140 <2.4 mg/kg	鬱廠繭鹹醖齋艱蓋淵鹹(構構夢鑰憲淵糧衊淵顧) = 廠廠製遞憲積餘鹹壓窪繭鏇築選艱構廠鬱糧網 (鹽夢繭壓憲遞壓衊鹹觸 ) 更多	积极	2024-09-16
NCT05464030 (ASCO2024) 人工标引	临床1期	转移性结直肠癌	40	M9140M9140 2.8 mg/kg	襯鑰糧蓋糧觸糧遞廠窪(衊網窪膚願遞糧遞膚鑰) = 壓齋蓋廠襯鏇鬱衊簾壓廠製簾鹹壓鹽製壓蓋餘 (範壓築製醖鏇鏇願顧築 ) 更多	积极	2024-05-24